Since 2015 we have been proud to partner and support clients who are at the forefront of creating groundbreaking new treatments and therapies.
We carefully select and recruit the highest calibre of personnel. Every member of
our team is an expert in their field and passionate about access for Rare Diseases.
As global experts in access for orphan drug, cell and gene therapy,
we truly understand the complexity and challenges of the market
access environment. P4A solutions are designed to be bespoke
to your situation, location and needs. One size does not fit all.
Our 2-minute promotional video will give you a thorough overview
into P4A and our tailored, meticulous and innovative approach.
We are an award-winning global consultancy and recognised
for excellence in access for orphan drugs & Cell and Gene Therapies.
Written by Iro Malekou, Senior Analyst & Srishti Gupta, Senior Consultant Emails: [email protected], [email protected] Over a year ago, the European Commission (EC) set out to
Vertex and CRISPR Therapeutics’ Casgevy became the first CRISPR gene therapy to be approved in the world after the UK’s MHRA granted conditional approval. Casgevy is indicated for the treatment of sickle cell disease and transfusion-dependent beta thalassemia, with the hope of being a potentially curative therapy for patients
Written by Marco Sancandi, PhD, Analyst. Email: [email protected] Rare diseases, individually infrequent but collectively prevalent, are in the spotlight as scientists strive to develop safer
